SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction: Expanding the Evidence.
Saved in:
| Title: | SGLT2 Inhibitors in Mitigating Cancer Therapy-Related Cardiac Dysfunction: Expanding the Evidence. |
|---|---|
| Authors: | Dabour MS; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.; Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt., Blaes AH; Division of Hematology/Oncology/Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA., Ramu B; Division of Cardiology, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA., Zordoky BN; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. |
| Source: | JACC. CardioOncology [JACC CardioOncol] 2024 Dec 17; Vol. 6 (6), pp. 876-878. Date of Electronic Publication: 2024 Dec 17 (Print Publication: 2024). |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101761697 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-0873 (Electronic) Linking ISSN: 26660873 NLM ISO Abbreviation: JACC CardioOncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
